759 related articles for article (PubMed ID: 28540743)
1. A review on cardiovascular effects of newer hypoglycaemic medications.
Cutshall BT; Twilla JD; Olinger AS; Oliphant CS
Ann Med; 2017 Nov; 49(7):603-612. PubMed ID: 28540743
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
Scheen AJ
Circ Res; 2018 May; 122(10):1439-1459. PubMed ID: 29748368
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
Thrasher J
Am J Med; 2017 Jun; 130(6S):S4-S17. PubMed ID: 28526182
[TBL] [Abstract][Full Text] [Related]
5. A Multifactorial Approach to Reduce Cardiovascular Disease in Type 2 Diabetes Mellitus: Now More Than Ever.
Basile JN
Hosp Pract (1995); 2016; 44(1):9-20. PubMed ID: 26781810
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
Paneni F; Lüscher TF
Am J Med; 2017 Jun; 130(6S):S18-S29. PubMed ID: 28526186
[TBL] [Abstract][Full Text] [Related]
7. Updates on cardiovascular outcome trials in diabetes.
Schnell O; Rydén L; Standl E; Ceriello A;
Cardiovasc Diabetol; 2017 Oct; 16(1):128. PubMed ID: 29020969
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies.
Ghosh RK; Bandyopadhyay D; Hajra A; Biswas M; Gupta A
Int J Cardiol; 2016 Jun; 212():29-36. PubMed ID: 27017118
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular safety of therapies for type 2 diabetes.
Gupta P; White WB
Expert Opin Drug Saf; 2017 Jan; 16(1):13-25. PubMed ID: 27652617
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
Thrasher J
Am J Cardiol; 2017 Jul; 120(1S):S4-S16. PubMed ID: 28606343
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
Paneni F; Lüscher TF
Am J Cardiol; 2017 Jul; 120(1S):S17-S27. PubMed ID: 28606340
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular outcome trials of the newer anti-diabetic medications.
Acharya T; Deedwania P
Prog Cardiovasc Dis; 2019; 62(4):342-348. PubMed ID: 31442511
[TBL] [Abstract][Full Text] [Related]
13. Glucose-Lowering Medications and Cardiovascular Outcomes.
Shanmugasundaram M; Pineda JRE; Murugapandian S
Curr Cardiol Rep; 2021 Mar; 23(4):24. PubMed ID: 33655453
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
[TBL] [Abstract][Full Text] [Related]
15. Update on Cardiovascular Effects of Older and Newer Anti-diabetic Medications.
Eleftheriadou I; Grigoropoulou P; Liberopoulos E; Liatis S; Kokkinos A; Tentolouris N
Curr Med Chem; 2018; 25(13):1549-1566. PubMed ID: 28554326
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective.
Thompson PL; Davis TME
Clin Ther; 2017 May; 39(5):1012-1025. PubMed ID: 27863704
[TBL] [Abstract][Full Text] [Related]
17. Making sense of newer treatment options for type 2 diabetes.
Lee PC; Hare MJL; Bach LA
Intern Med J; 2018 Jul; 48(7):762-769. PubMed ID: 29984503
[TBL] [Abstract][Full Text] [Related]
18. [The combination of GLP-1 analogs and SGLT2 inhibitors : new perspectives ?].
Ritz C; Jaafar J; Philippe J
Rev Med Suisse; 2017 May; 13(565):1134-1139. PubMed ID: 28639755
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular and Renal Outcomes of Newer Anti-Diabetic Medications in High-Risk Patients.
Lawrence L; Menon V; Kashyap S
Curr Cardiol Rep; 2018 Jun; 20(8):65. PubMed ID: 29926285
[TBL] [Abstract][Full Text] [Related]
20. Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases.
Prattichizzo F; La Sala L; Rydén L; Marx N; Ferrini M; Valensi P; Ceriello A
Eur J Prev Cardiol; 2019 Dec; 26(2_suppl):73-80. PubMed ID: 31766918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
